A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.

CONCLUSIONS: Although this immunomodulating formula failed to reduce severe mucositis during CRT, the findings suggest that the long-term survival of compliant HNSCC patients was improved.This trial was registered at clinicaltrials.gov as NCT01149642. PMID: 32936874 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32936874?dopt=Abstract

Source: The American Journal of Clinical Nutrition - September 15, 2020 Category: Nutrition Authors: Boisselier P, Kaminsky MC, Thézenas S, Gallocher O, Lavau-Denes S, Garcia-Ramirez M, Alfonsi M, Cupissol D, de Forges H, Janiszewski C, Geoffrois L, Sire C, Senesse P, Head and Neck Oncology and Radiotherapy Group (GORTEC) Tags: Am J Clin Nutr Source Type: research